drugset / Trial / NCT02429622

Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma

NCT02429622

Phase 1/2 Completed 80 enrolled Chinese Academy of Medical Sciences
Non-randomizedParallel-groupSingle-blindTreatment

Summary

This phase Ⅰ/Ⅱ trial is designed to explore a higher radiation dose by using IMRT simultaneous integrated boost technique with or without concurrent chemotherapy for locally advanced esophageal carcinoma.

Timeline

Start
2015-01
Primary completion
2016-10
Completion
2016-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Nedaplatin Small molecule 25 mg/m2
Subject Paclitaxel Small molecule 45 mg/m2
Subject Paclitaxel Small molecule 60 mg/m2